Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505904 | 0.96 | NR4A2 (0.61) | NR4A2KMT2AMEP1BESR1MRGPRX4 | |
| SCHEMBL1122672 | 0.84 | PKM (0.63) | NR4A2KMT2AESR1SRD5A2MAOB | |
| SCHEMBL4299737 | 0.83 | KMT2A (0.70) | NR4A2KMT2AESR1MAOBNR1H4 | |
| SCHEMBL5936607 | 0.81 | KDM4E (0.49) | NR4A2KMT2AESR1MAOBLPAR1 | |
| SCHEMBL1168167 | 0.81 | NR4A2 (0.71) | NR4A2KMT2AMRGPRX4SRD5A2LPAR1 | |
| SCHEMBL30869931 | 0.81 | NR4A2 (0.71) | NR4A2KMT2AMRGPRX4SRD5A2LPAR1 | |
| SCHEMBL5936602 | 0.80 | HDAC1 (0.48) | KMT2ANR1H4 | |
| SCHEMBL5936618 | 0.80 | NR4A2 (0.52) | NR4A2KMT2ASRD5A2MAOB | |
| SCHEMBL5936595 | 0.80 | KDM4E (0.51) | NR4A2KMT2AESR1MAOBLPAR1 | |
| SCHEMBL6932542 | 0.80 | KMT2A (0.75) | NR4A2KMT2AMRGPRX4NR1H4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1644321-A2 | NEW BENZAMIDES AS PPATY MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004110983-A2 | NEW BENZAMIDES AS PPARϒ MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | NR4A2 66/4885KMT2A 1515/4885MEP1B 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.